Cure8 research brief
This preclinical study suggests that a specific gut microbe (Bacteroides acidifaciens) and the bile acid UDCA can reduce inflammation in a mouse colitis model by improving barrier function and dampening NLRP3-driven cytokine release.
If findings translate to humans, modulating microbiota or UDCA pathways could become a non-helminth-based strategy for IBD treatment.
Researchers studying the microbiome, bile-acid signaling, or innate immune pathways in IBD; clinicians interested in future microbiota-targeted therapies; patients curious about preclinical progress (not clinical recommendations).
This article reports a preclinical (mouse) study and integrated microbiome/metabolomics analysis showing that Trichinella spiralis infection changed gut bacteria and increased levels of the bile acid ursodeoxycholic acid (UDCA). Transferring microbiota from infected mice, or giving UDCA–related interventions, reduced TNBS-colitis severity in mice.
The authors identify Bacteroides acidifaciens as a producer of bile salt hydrolase that helps generate UDCA, and they present cellular data that UDCA signals via the bile acid receptor TGR5 on macrophages and dendritic cells to inhibit NLRP3 inflammasome activation and lower IL-1β/IL-18, with improvements in tight junction proteins and barrier integrity.
The study is preclinical and uses mouse colitis models, fecal microbiota transplantation, metagenomics, metabolomics, and cellular/mechanistic assays. It suggests targeting specific microbes or UDCA as a microbiota-targeted therapeutic direction, but does not provide clinical trial or human efficacy data.
Who to contact for details: read the full Research Square posting and the linked preprint/paper (authors and affiliations listed on the source) for experimental methods, raw data, and any subsequent peer-reviewed publication.
This is a preclinical mouse study posted on Research Square (abstract/full-text available). Preclinical mechanisms do not guarantee benefit in humans; safety, dosing, and clinical efficacy would require formal clinical trials. Research Square postings can represent early-stage or preprint material prior to peer-reviewed publication.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If environmental microplastics contribute to gut dysbiosis and mucosal inflammation, this could help explain environmental triggers of ulcerative colitis and point toward prevention or microbiome-targeted interventions.
This review may help patients and clinicians understand how long-lasting changes in bacterial metabolism could contribute to IBD relapse and point toward future microbiome-targeted therapies aimed at restoring resilient...
The article connects psoriasis and Crohn's disease through shared immune pathways and the gut-skin axis, which may matter because people with one condition could have signs or risks related to the other. It emphasizes...
